Prometheus' Dx pipeline is very compelling. I think that through direct bills and the sleazy sales efforts of a select few, it will barely be enough to pump the numbers up right around the IPO date. Unfortunately, most of us will have to wait several years to unload our options (read the fine print), and the higher ups will have a pretty good pay day initially. Long term, things don't look so good. Dx's that no one wants to pay for, and is it really clinically valuable? And, Rx's that are red-headed step-children of companies with a real pharma pipeline.
The kool-aid is getting pretty thin, and the crab cakes are nonexistent.